对接受联合化疗的转移性乳腺癌患者的总生存时间无相关影响。
No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy.
作者信息
Petru E, Schmähl D
机构信息
Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
出版信息
J Cancer Res Clin Oncol. 1988;114(2):183-5. doi: 10.1007/BF00417834.
Abstract
The results of clinical studies dealing with first and second line chemotherapy of metastatic breast cancer published between 1975 and early 1986 which involved 9350 women were reviewed. Our special aim was to evaluate combination chemotherapy and its influence on overall survival in late stage breast cancer patients. No significant improvement in overall survival times was found in this selected group of patients who were treated with intense palliative chemotherapy.
摘要
对1975年至1986年初发表的涉及9350名女性的转移性乳腺癌一线和二线化疗临床研究结果进行了回顾。我们的特别目的是评估联合化疗及其对晚期乳腺癌患者总生存期的影响。在接受强化姑息化疗的这组选定患者中，未发现总生存时间有显著改善。
相似文献
1
No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy.
J Cancer Res Clin Oncol. 1988;114(2):183-5. doi: 10.1007/BF00417834.
2
Combination versus sequential single agent chemotherapy for metastatic breast cancer.
Cochrane Database Syst Rev. 2013 Dec 18;2013(12):CD008792. doi: 10.1002/14651858.CD008792.pub2.
3
Platinum-containing regimens for metastatic breast cancer.
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
4
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Single agent versus combination chemotherapy for metastatic breast cancer.
Cochrane Database Syst Rev. 2005 Apr 18(2):CD003372. doi: 10.1002/14651858.CD003372.pub2.
6
Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD003368. doi: 10.1002/14651858.CD003368.pub2.
7
Systemic therapy for treating locoregional recurrence in women with breast cancer.
Cochrane Database Syst Rev. 2001;2001(4):CD002195. doi: 10.1002/14651858.CD002195.
8
Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003368. doi: 10.1002/14651858.CD003368.pub3.
9
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study.
J Chemother. 2025 Jul;37(4):334-340. doi: 10.1080/1120009X.2024.2366683. Epub 2024 Jun 21.
10
Platinum containing regimens for metastatic breast cancer.
Cochrane Database Syst Rev. 2004(3):CD003374. doi: 10.1002/14651858.CD003374.pub3.
引用本文的文献
1
Postmenopausal breast cancer. Drug therapy in the 1990s.
Drugs Aging. 1993 Mar-Apr;3(2):106-21. doi: 10.2165/00002512-199303020-00002.
2
[Janus-faced character of chemotherapy: a comment on the Abel theses].
Klin Wochenschr. 1991 Jan 4;69(1):49-51. doi: 10.1007/BF01649059.
本文引用的文献
1
Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2'-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors.
Cancer Treat Rep. 1985 Dec;69(12):1415-24.
2
Estrogen-linked 2-chloroethylnitrosoureas: anticancer efficacy in MNU-induced rat mammary carcinoma, uterine activity in mice and receptor interactions.
Eur J Cancer Clin Oncol. 1986 Oct;22(10):1179-91. doi: 10.1016/0277-5379(86)90319-6.
3
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.
Wien Klin Wochenschr. 1986 Dec 5;98(23):790-7.
4
[Importance of the composition of various combination regimens in the chemotherapy of metastatic breast cancer].
Dtsch Med Wochenschr. 1987 Feb 13;112(7):270-5. doi: 10.1055/s-2008-1068044.
5
Antimetastatic effects of razoxane in a rat osteosarcoma model.
Clin Exp Metastasis. 1987 Jan-Mar;5(1):9-16. doi: 10.1007/BF00116621.
6
Alkyl phosphocholines: toxicity and anticancer properties.
Lipids. 1987 Nov;22(11):930-4. doi: 10.1007/BF02535558.
7
Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?
Cancer. 1986 Feb 1;57(3):567-70. doi: 10.1002/1097-0142(19860201)57:3<567::aid-cncr2820570328>3.0.co;2-y.
Zotero 插件